MANAGEMENT OF SLOW COLONIC TRANSIT CONSTIPATION IN PARKINSON'S DISEASE: CURRENT EVIDENCE AND A COMMUNITY PHARMACY PERSPECTIVE by Johnson, Michaela E & Johnson, Jacinta L.
 
Review Article 
MANAGEMENT OF SLOW COLONIC TRANSIT CONSTIPATION IN PARKINSON’S DISEASE: 
CURRENT EVIDENCE AND A COMMUNITY PHARMACY PERSPECTIVE 
 
MICHAELA E JOHNSON1, JACINTA L JOHNSON1,2 
1School of Pharmacy and Medical Sciences, Sansom Institute for Health Research, University of South Australia, Adelaide, SA 5000 
(Australia), 2SA Pharmacy, SA Health. Division of Pharmacy, Flinders Medical Centre, Australia 
Email: jacinta.johnson@unisa.edu.au      
 Received: 30 Mar 2016 Revised and Accepted: 17 May 2016 
ABSTRACT 
The non-motor symptoms of Parkinson's disease are often under-recognised and undertreated. Constipation is exceedingly common in Parkinson's 
disease, reportedly affecting up to 70% of patients. Pharmacists are ideally positioned to screen patients with Parkinson's disease for constipation 
and to optimise constipation management. This review will describe the evidence base for the use of different treatments in the management of 
constipation in patients with Parkinson's disease. PubMed, Embase and Web of Science were searched using the following search terms: 
"constipation" OR "gastrointestinal dysfunction" OR "slow colonic transit" OR "defecatory dysfunction" OR "slow motility" AND "treatment" OR 
"management" OR "therapy" AND "Parkinson* disease". The literature indicates macrogol is a safe and effective treatment for constipation in 
Parkinson’s disease; it should be considered a first line treatment and can be recommended by the pharmacist over-the-counter. Pharmacists can 
provide information regarding fibre supplementation with psyllium, which may be effective and can be initiated early. Lubiprostone appears to be a 
promising option, but larger and longer trials are warranted. Although many commonly employed treatments for constipation have not been 
evaluated for efficacy in Parkinson's disease, pharmacists can utilise available data to make evidence-based recommendations to optimise 
management of constipation and improve patient quality of life.  
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INTRODUCTION 
While the typical motor symptoms of Parkinson’s disease (PD) are 
well known, the wide array of non-motor symptoms associated with 
this condition are often under-recognised and therefore 
undertreated. Patients report non-motor symptoms such as sleep 
disorders, loss of sense of smell, depression and gastrointestinal 
symptoms to have a greater burden on their day-to-day life than 
their motor-symptoms do [1]. Parkinson’s patients suffer various 
gastrointestinal disturbances, which can present across different 
stages of the disease and in all parts of the gastrointestinal tract 
leading to symptoms ranging from drooling to reflux and constipation 
[2]. Constipation is the most common gastrointestinal disturbance in 
PD, with a reported prevalence ranging from approximately 15 to 70% 
[3-5]. The two main causes of constipation in patients with PD are 
slow colonic transit and defaecatory dysfunction [6].  
In PD, slowing of colonic transit is likely due to impaired peristalsis 
[7], which in turn may be attributed to the presence of Lewy bodies 
(proteinaceous cytoplasmic inclusions) in the enteric nervous 
system (ENS) [8-12] and dorsal motor nucleus of the vagus (DMV) of 
the spinal cord as well as severe degeneration in the DMV [13]. Loss 
of dopaminergic enteric neurons has also been reported in patients 
with PD [14], although the clinical significance of this is unclear as 
these dopamine cells only represent 1-2% of the total ENS 
population and are thought to play an inhibitory role on gut motility. 
It is possible that by losing these inhibitory signals the 
gastrointestinal tract is not able to optimally perform the 
coordinated action of contraction and relaxation required for 
peristalsis. Not all studies have reported a loss of neurons in the 
myenteric plexus; prior reports found no change in the amount of 
nitric oxide, vasoactive intestinal polypeptide or catecholamine 
expressing neurons in PD patients compared to healthy controls [11, 
13]. In addition to the pathological changes that occur in PD, 
dopaminergic and anticholinergic treatments can contribute to 
constipation. While constipation may worsen following the initiation 
of dopaminergic treatment [15, 16], such drugs cannot be the sole 
cause of this symptom as constipation is present in many patients 
prior to pharmacological intervention [17]. 
Defaecatory dysfunction, the other cause of constipation in 
Parkinson’s patients, is due to disruption of the coordinated activity 
required for faecal expulsion. The physiological defaecation process 
involves relaxation of the puborectalis muscles to open the anorectal 
angle, reflex opening of the internal anal sphincter and voluntary 
relaxation of the external anal sphincter [9, 18]. This action is 
mediated by reciprocal interactions between neurons in the sacral 
parasympathetic nucleus of the spinal cord and Onuf’s nucleus in the 
sacral cord, which innervates the external sphincter and pelvic floor 
[19]. The sacral defaecation reflex is also regulated by supraspinal 
mechanisms such as the descending inputs of the medullary raphe 
nuclei to Onuf’s nucleus [20]. The medullary raphe nuclei is reported 
to be affected in early PD, therefore the activation, instead of 
inhibition, of Onuf’s motoneurons seen in PD could be due to 
impaired modulation from supraspinal mechanisms, ultimately 
resulting in the passing of fewer stools or incomplete defaecation. 
Parkinson’s patients are reported to have α-synuclein pathology in 
the lateral collateral pathway, a region of the sacral spinal dorsal 
horn important for the relay of pelvic visceral afferents, this is also 
likely to contribute to defaecatory dysfunction constipation [21]. 
Defaecatory dysfunction constipation is very difficult to treat as routine 
laxatives fail to improve the impaired anorectal muscular coordination. 
Specific treatments include botulinum-toxin injections into the 
puborectalis muscle and sacral nerve stimulation, both of which require 
specialist medical care. As the pathology of constipation in the 
Parkinson’s patient population may differ from other presentations of 
chronic constipation, management should include treatments that have 
been evaluated specifically in this patient group. 
Braak and colleagues staging of PD states the gastrointestinal tract 
as one of the earliest regions to develop Lewy body pathology, 
suggesting unidentified toxins may cross the mucosal barrier of the 
intestine inducing pathology in the axon terminal of the vagus nerve, 
which subsequently progresses in a retrograde manner to the brain 
[22]. Once in the brain damage can occur to the dopamine-producing 
cells in the substantia nigra, resulting in development of the typical 
motor symptoms [8]. In line with Braaks hypothesis, several studies 
have reported constipation develops up to 20 y earlier than the 
motor symptoms [23, 24]. Due to this early presentation patients 
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may not associate the gastrointestinal disturbance and their PD and 
therefore fail to discuss the problem with their doctor or 
neurologist. Pharmacists are therefore in an ideal position to screen 
patients with PD for constipation when they present to have their 
motor-symptom medication dispensed. The pharmacist can use this 
opportunity to question appropriately and provide advice regarding 
the management of constipation in this patient group, to allow early 
intervention and substantially boost patient outcomes. Early 
identification is important to prevent progression to serious 
complications such as intestinal pseudo-obstruction, bowel 
perforation, sigmoid volvulus and megacolon, which may require 
surgical treatment [2, 25, 26]. 
This review will focus on the evidence base for effective treatment of 
slow colonic transit constipation in PD and provide commentary 
regarding the important role the pharmacist can play in screening 
for and in providing treatment advice to improve quality of life for 
patients with PD. 
Screening for constipation in patients with Parkinson’s disease 
in community pharmacy practice 
Screening for constipation can be challenging as frequency of bowel 
movements can vary considerably between individuals, therefore it 
is usually the change in bowel movements that is diagnostic [27]. In 
patients with PD, constipation may have developed slowly over 
many years, making a distinct change in bowel habits difficult to 
discern. Thus, a detailed assessment is required to establish if 
constipation is present; for suggested screening questions the 
pharmacist can use in conversation with patients with PD see table 
1. Constipation should be screened for when the patient first 
presents to the pharmacy with a diagnosis of Parkinson's disease, for 
example when they first present to fill a prescription for motor-
symptom medication. The pharmacist then has the opportunity to 
monitor symptoms by asking about changes in bowel habits as the 
patient presents regularly to have their motor-symptom medication 
dispensed. The pharmacist can also play a key role in educating the 
patient regarding the link between constipation and PD so they can 
self-monitor for indicative symptoms. Once constipation has been 
confirmed the pharmacist should screen for reversible causes (see 
table 2 for suggested questions to establish contributing factors) and 
for ‘red flag’ symptoms, which indicate referral to a medical 
practitioner is warranted (see table 3).  
In patients with PD, if defaecatory dysfunction is suspected 
(characterised by excessive straining, accompanied by pain and a 
sense of incomplete evacuation), the patient should be referred to 
their medical practitioner, as over-the-counter treatments are 
typically ineffective. 
 
Table 1: Suggested screening questions to determine if the patient is likely to be experiencing constipation [28-30] 
Screening questions  Response criteria 
On average, could you estimate how many bowel movements 
you have had per w over the last 3 w? 
 Less than three per w is usually indicative of constipation. 
Do you have pain, discomfort or a sensation of incomplete 
evacuation when having a bowel movement?  
 Positive response can indicate constipation.  
Would you say the consistency of the stool was hard, soft or 
normal?  
 Hard consistency would be considered a sign of slow colonic transit 
constipation. 
How often have you had to strain during bowel movements 
over the last 12 w? 
 Straining for greater than 25% of bowel movements suggests constipation. 
Have you had to take laxatives or perform any manual 
manoeuvrers to pass a bowel motion over the last 12 w? If so, 
how often? 
 A positive response indicates faecal impaction. If intervention was necessary 
for greater than 25% of bowel movements in the last 12 w it suggests 
constipation. 
How often do you have difficulty relaxing or letting go to allow 
the stool to come out during a bowel movement? 
 This is indicative of defaecatory dysfunction. 
 
Table 2: Screening questions to assess contributing factors and/or underlying cause/s of constipation [31, 32] 
Screening questions  Response criteria 
When did your symptoms begin? Did 
your symptoms come on suddenly or 
gradually worse over time? 
 Determining time and manner of onset can help identify the underlying cause by establishing time-
course relationships. 
On average how much water and other 
fluids do you drink per d? Has your 
fluid intake changed recently? 
 Inadequate fluid intake can lead to constipation. Suggested adequate intake of fluids is at least 2 l per 
d. 
Does your diet include foods high in 
fibre? 
Have you recently changed your diet? 
Has you intake of foods high in fibre 
increased or decreased? 
 A low fibre diet may predispose to constipation. Insoluble fibre (e. g. legumes, skins of fruit and 
vegetables, wholegrain foods) and soluble fibre (e. g. oats, psyllium husk, fruits and vegetables) can be 
effective in preventing or alleviating constipation in those with inadequate baseline intake. 
Do you engage in regular physical 
activity? Has your activity level 
changed recently? 
 Insufficient physical activity may predispose to constipation. Constipation may develop during 
periods of inactivity, e. g. while recovering from an injury. 
Do you ever suppress the urge to pass a 
bowel movement? 
 Responding immediately to the urge to defaecate may provide a benefit in those with constipation. 
Are you currently taking any 
medications? 
 Medications that can cause constipation include:  
• antacids containing aluminium and calcium 
• some anticonvulsants (e. g. carbamazepine, phenytoin, pregabalin) 
• antidepressants (tricyclic antidepressants and monoamine oxidase inhibitors) 
• sedating antihistamines 
• antimuscarinic drugs 
• many antipsychotics (e. g. olanzapine, risperidone, quetiapine) 
• calcium supplements 
• clonidine 
• diuretics 
• dopaminergic drugs 
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• opioid analgesics 
• sucralfate 
• verapamil 
• vinca alkaloids 
• 5-hydroxytryptamine (5HT3) receptor antagonists 
Do you have any other medical 
conditions? (in addition to Parkinson's 
disease)  
 Relevant medical conditions which may be predispose to constipation include:  
• coeliac disease 
• psychiatric conditions (e. g. depression, anxiety) 
• diabetes mellitus 
• hypothyroidism 
• irritable bowel syndrome 
• multiple sclerosis 
 
Table 3: A list of ‘red flag’ symptoms, which indicate referral to a medical practitioner is warranted [31, 33] 
Red flag symptoms 
Persistent or severe abdominal pain 
Nausea and vomiting 
Constipation alternating with diarrhoea 
Unintentional weight loss 
Blood and/or mucus in the stool (including black ‘tarry’ stool) 
Tenesmus (continuous feeling of the need to defaecate) 
Fever  
Sudden change in bowel habit>2 w in duration, not attributable to changes in diet or lifestyle, a medical condition or medication 
Rectal pain causing the patient to suppress the defaecatory reflex 
 
MATERIALS AND METHODS 
Papers for review were identified through an electronic search of 
PubMed, Embase and Web of Science databases (Feb 2016) using the 
following search terms: "constipation" OR "gastrointestinal 
dysfunction" OR "slow colonic transit" OR "defecatory dysfunction" 
OR "slow motility" AND "treatment" OR "management" OR "therapy" 
AND "Parkinson* disease". Reference lists of articles identified 
through initial search were reviewed to identify additional articles of 
relevance. Only papers published in English were included.  
DISCUSSION 
Management of slow colonic transit constipation in Parkinson’s 
disease 
Differences in the underlying cause of constipation in patients with 
PD mean different treatments strategies are appropriate for slow 
colonic transit constipation compared with defaecatory dysfunction. 
As slow colonic transit is exceedingly common in patients with PD 
[34], this review will focus on the evidence for treatments used for 
this form of constipation. 
Dietary and lifestyle interventions 
Before recommending a pharmacological intervention for constipation 
in PD, as with other patient groups experiencing constipation, the 
pharmacist should provide advice regarding lifestyle modifications that 
can be trialled. Such interventions include increasing and/or 
supplementing dietary fibre and increasing fluid intake as well as 
increasing exercise levels. However, the pharmacist will need to weigh 
up the efficacy and appropriateness of these measures in light of the 
stage of PD the patient is experiencing, as discussed below. 
Increased fluid intake 
Patients suffering from constipation are often advised to increase 
their fluid intake, yet data to support this recommendation are 
surprisingly scarce. Clinical studies investigating constipation in 
multiple populations have demonstrated only minimal benefit in 
terms of changes in stool frequency, stool consistency and difficulty 
during defaecation, with benefits deemed unlikely to be clinically 
relevant [35-37]. Increasing fluid intake alone may only attenuate 
constipation in those with insufficient fluid intake [38]. 
Patients with PD, particularly advanced disease, present with a 
higher risk of dehydration than the general population as 
gastrointestinal symptoms, such as drooling and difficulty 
swallowing, could lead to reduced fluid intake [23]. Hence, it is 
possible this patient group may respond better to increased fluid 
intake than others who suffer from chronic constipation. Ueki and 
Otsuka [23] investigated the potential association between 
decreased water intake and constipation in 94 patients with PD. 
Total water intake was significantly lower in PD patients, than in 
controls and 70% of the patients were defined as having 
constipation. The amount of water consumed in patients with PD 
was inversely correlated with severity of constipation. Intriguingly, 
PD patients also tended to not feel thirsty and therefore had little 
desire to drink water throughout their life, suggesting water 
depletion may have preceded the development of constipation [23]. 
Increased dietary fibre intake 
Astarloa and Mena [39] have demonstrated that when Parkinson’s 
patients increase their daily intake of insoluble dietary fibre from 
approximately 10 g to 28 g they have a significant improvement in 
their severity of constipation. This dietary intervention also 
produced improvements in the patients’ motor scoring likely due to 
better absorption of L-dopa, which was evident by substantially 
higher total plasma L-dopa levels [39]. In Astarloa’s study the 
increase in fibre was achieved through supplementation with a 
mixture of tablets containing wheat bran, pectin and dimethyl-
polyoxylhexane-900. This approach may be particularly suitable for 
patients with advanced PD that may have low fibre intake as a result 
of difficulties in chewing, which often accompanies high fibre foods. 
Another viable option to introduce higher amounts of fibre in a PD 
patients’ diet is consumption of fibre supplements such as psyllium 
(botanical name: plantago ovate, also known as ispaghula husk), 
which functions as a bulk-forming laxative. Ashraf and Pfeiffer [40] 
assessed the effect of psyllium on constipation in PD, in a small 
randomised placebo-controlled trial, finding that although psyllium 
increases stool weight and frequency, it does not change colonic 
transit or anorectal function.  
Increased physical activity  
To date no studies have directly assessed whether increasing 
exercise attenuates constipation in patients with PD. However, 
exercise may produce the same improvement in defaecation pattern 
and colonic transit time for this sub-group as it does for others 
suffering chronic idiopathic constipation [41]. Leading a sedentary 
lifestyle is associated with an increased risk of developing 
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constipation [42], and may therefore be playing a role in 
constipation in PD patients whose debilitating motor symptoms and 
increased risk of falls and fall-related injuries, such as fractures, 
leads to a more inactive lifestyle [43, 44]. Importantly, health care 
professionals need to weigh the benefit: risk ratio of different forms 
of physical activity on an individual basis in patients with PD as their 
higher risks of falls may render some exercise interventions too 
unsafe for the potential benefit [45, 46]. 
Dietary probiotic supplements 
Currently only one study has assessed the effect of probiotics on 
constipation in PD. In this study, the authors reported the 
combination of dietary intervention (following nutritional 
recommendations for fluid and fibre intake) with 65 ml of fermented 
milk containing Lactobacillus casei Shirota daily, had superior effects 
than dietary intervention alone [47]. Specifically, the probiotics were 
able to improve stool consistency, bloating, abdominal pain and the 
sensation of incomplete evacuation in patients that showed no 
improvement from the just dietary intervention. The use of 
probiotics may have the additional benefit of repopulating the bowel 
with normal flora as PD patients have been shown to have an 
increased prevalence of small intestinal bacterial overgrowth [48, 
49]. Treating PD patients who have small intestinal bacterial 
overgrowth can potentially also improve the patients’ motor 
symptoms as these patients tend to have longer off-time in response 
to their medication and worse motor fluctuations [50].  
Pharmacological interventions 
If non-pharmacological interventions, including bulking agents, are 
unsuccessful or inappropriate, the pharmacist can provide advice 
regarding pharmacological laxatives, which can be added for the 
management of constipation. A variety of over-the-counter and 
prescription treatments are available, ranging from osmotic 
laxatives and stool softeners to stimulant laxatives and 
secretagogues. In general, evidence to substantiate the relative 
efficacy and tolerability of the different types of laxatives is scarce, 
thus pharmacist-led drug selection should be based upon factors 
such as the required onset of action, hardness of stool, patient 
preference, adverse effects, effectiveness of previous treatments and 
cost [51]. Differences in the underlying constipation pathology may 
also influence the efficacy of specific treatments. The following 
section outlines the direct evidence for the use of different types of 
laxatives for constipation in patients with PD, in the context of 
efficacy data for constipation in other populations. 
Osmotic laxatives 
There is more evidence for the efficacy for macrogols (also known as 
polyethylene glycols), in constipation in PD patients than for any 
other laxatives available over the counter. Macrogol 3350, 
commonly administered in a formulation containing electrolytes to 
minimise electrolyte and water loss, works by increasing the water 
content and volume of the stool. It achieves this by increasing the 
osmolality of the gastrointestinal lumen, thereby stimulating water 
to enter the lumen to balance the osmolality. The osmotic action of 
macrogol results from its high water binding capacity [52].  
Two studies, one open-labelled and the other a randomised, double-
blind parallel group study, have assessed the benefit of macrogol for 
constipation in PD patients, both reporting positive outcomes in 
terms of more frequent bowel movements, softened stool 
consistency, increased ease of defaecation and a reduced need of 
rectal laxatives [52, 53]. Zangaglia and Martignoni [53] administered 
either placebo (flavoured maltodextrine in 250 ml water) or 
macrogol electrolyte solution (7.3 g in 250 ml water) twice a d for 8-
w. Their intervention was well tolerated and considered safe with 
minimal risk in patients with PD [53, 54].  
Other osmotic laxatives such as lactulose, lactitol, sorbitol and 
mannitol are yet to be directly assessed in PD patients. In other 
types of constipation such as opiate-induced constipation, 
polyethylene glycol 3350+electrolytes is reported to be more 
effective with fewer adverse effects than lactulose [55]. Similarly, in 
hospitalised patients macrogol with electrolytes is more effective 
than treatment with psyllium [56]. 
Rectal osmotic laxative formulations contain poorly absorbed ions 
such as magnesium, sulfate, phosphate and citrate, which retain fluid 
in the colon by osmotic effect and stimulate peristalsis [51]. While 
no studies have compared oral laxatives with rectal formulations in 
PD patients, rescue treatment with rectal laxatives (enemas) can be 
trialled if oral medications have failed [57]. 
Stool softeners 
Stool softeners used in the management of constipation include 
docusate, poloxamer, liquid paraffin (also known as mineral oil), 
seed oils and arachis oil. No studies have investigated the efficacy of 
stool softeners in constipation associated with PD. 
In other groups suffering constipation, docusate is the most widely 
used stool softener. Docusate sodium (dioctyl sodium sulpho-
succinate) is a synthetic anionic detergent; it assists in the treatment of 
constipation by reducing surface tension, thereby allowing penetration 
of water and fats into the faeces. Although initiation of a stool softening 
agent is often regarded as the first step in treating constipation, at least 
one study suggests psyllium is superior to docusate, furthermore, in 
other states of refractory constipation, such as opioid-induced 
constipation, stool softeners alone are generally insufficient. Thus, the 
role for stool softeners as a sole therapy for constipation in patients 
with PD is likely to be limited. 
Liquid paraffin, seed oils and arachis oil work as lubricants to assist 
faecal movement, despite being used clinically for decades, evidence 
of efficacy has not been demonstrated in randomised, controlled 
trials [56]. Furthermore, these treatments carry the risk of lipoid 
pneumonia if aspirated, and are therefore contraindicated in 
patients at risk of aspiration [58]. Given ‘silent’ aspiration without 
any recognisable swallowing difficulty is common in patients with 
PD [59], liquid paraffin and oral seed/arachis oils should be avoided 
in this patient group. 
Stimulants  
Stimulant laxatives, such as senna and bisocodyl aid in constipation 
by promoting intestinal motility, thereby reducing the time for 
absorption of salt and water. Such drugs also increase release of 
histamine, serotonin and prostaglandins in the colon, of these 
mediators, prostaglandins are thought to be the most important in 
increasing bowel movements. As is the case for stool softeners, no 
stimulant laxatives have been evaluated specifically in PD. 
Prokinetics 
Prokinetic drugs are usually reserved for refractory cases of 
constipation. Cisapride, tegaserod, mosapride and prucalopride are 
5-HT4 receptor agonists that have been evaluated for treatment in 
constipation. Activation of serotonergic receptors in the 
gastrointestinal tract assists in treating constipation by stimulating 
peristalsis, increasing intestinal secretions and reducing visceral 
hypersensitivity.  
Cisapride also stimulates gastrointestinal motility by promoting the 
physiological release of acetylcholine from the postganglionic nerve 
endings of the myenteric plexus. In contrast to many constipation 
treatments, cisapride has been investigated specifically for 
constipation in PD in 3 clinical trials. In a pilot study all 20 PD 
patients benefited from cisapride 5 mg twice a d, demonstrating 
reduce colonic transit time radiographically [34]. In a further study 
cisapride 10 mg twice a d was found to accelerate colonic transit 
time by approximately 40% in this patient group [60]. 
Unfortunately, a long-term follow up study, in which patients were 
treated with cisapride 10 mg twice a d, observed reduced efficacy at 
6 mo, and virtually no benefit over baseline following one year of 
sustained use [61]. 
Cisapride however, was withdrawn from the market world-wide 
following reports of serious cardiac events [62], thought to results 
from its effects on human ether-a-go-go-related gene (hERG) 
potassium channels. In many countries cisapride remains available 
only via special or compassionate access schemes for use in 
gastroparesis under specialist care. Tegaserod, a partial 5-HT4 
agonist found to be beneficial in the management of constipation in 
PD in an open label study [63] but not in a small randomised 
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controlled trial [64], has similarly been withdrawn due to 
cardiovascular toxicity concerns. 
Unlike cisapride, the 5-HT4 agonist mosapride is devoid of D2 
dopaminergic and hERG potassium channel blocking effects. It 
has also been tested in a small number of patients with PD in an 
open label Japanese trial [65]. In this trial a dose of 15 mg per d 
was effective in shortening colon transit time, improving 
subjective bowel movement frequency and reducing difficult 
defaecation [65]. Mosapride was well tolerated by 6 of 7 PD 
patients, with one patient ceasing treatment due to epigastric 
pain [65]. Accessibility limits clinical use in many countries, 
while it is available in parts of Asia and South America, it is not 
on the market in the US, Europe, the UK or Australia. Further 
larger, randomised studies should be performed before 
mosapride can be recommended in PD. 
Prucalopride, another 5-HT4 agonist that does not inhibit hERG 
potassium channels, is more widely available than mosapride (on 
the market in Australia, Canada, Europe, the UK and some parts of 
Asia), although it has not yet been approved by the US Food and 
Drugs Administration (FDA). To date prucalopride has not been 
studied in the PD population and results in patients with severe 
chronic constipation have been inconsistent. Prucalopride, dosed at 
either 2 mg or 4 mg once daily, did significantly improve bowel habit 
assessments relative to placebo in three large, randomized, double-
blind, 12-w trials in patients with severe chronic constipation [66]. 
However, a trial published earlier this year failed to find an increase 
in the frequency of spontaneous, complete bowel movement vs. 
placebo using 2 mg daily dose over 24 w. In light of these 
inconsistent results and lack of population-specific data, 
prucalopride is not yet recommended in PD. New generations of 
highly selective 5-HT4 agonists under development (velusetrag, 
noranopride) are hoped to progress to provide prokinetic options 
with greater efficacy and safety [67].  
Other traditional prokinetics include dopamine antagonists 
domperidone and metocolpramide. However of the two dopamine-2 
receptor antagonists used clinically, only domperidone is suitable 
for use in patients with PD as it does not reach the central nervous 
system. Metoclopramide must be avoided as it crosses the blood-
brain barrier leading to blockade of central dopamine receptors, 
which can quickly exacerbate parkinsonian symptoms. 
Domperidone improves nausea and reflux symptoms in PD, however 
the beneficial effects seen it the upper gastrointestinal tract were not 
observed in patients with constipation [68]. It should also be noted 
that domperidone increases levodopa absorption and subsequently 
produces motor benefits. In patients with PD domperidone has been 
trialed for various indications in doses from 10 mg to 120 mg daily; 
despite this doses above 30 mg/d, should be used with particular 
caution due to the risk of arrhythmia, sudden death and cardiac 
arrest, especially in patients with additional risk factors for QTc 
interval prolongation [69]. Although domperidone is not FDA 
approved it is widely available elsewhere, and is even accessible 
over the counter in some regions. The pharmacist has a critical role 
in screening for drug interactions between domperidone and 
cytochrome P450 3A4 inhibitors, p-glycoprotein inhibitors or other 
drugs that can prolong the QTc interval in PD patients, particularly 
in areas where domperidone is available without a prescription. 
Secretagogues 
Lubiprostone is a well-tolerated, FDA approved bicyclic fatty acid 
metabolite analogue of prostaglandin E1 that works by activating type-
2-chloride channels on the mucosal epithelia [70]. Studies have shown 
that lubiprostone dose-dependently increases fluid secretion in the 
intestinal lumen, which is thought to contribute in the improvement of 
constipation [71]. Ondo and Kenney [72] performed a double blind, 
randomized, controlled trial assessing the effectiveness of 
lubiprostone for short-term relief of constipation in 54 patients with 
PD. In this study, lubiprostone titrated up to a dose of 24 microg 
twice daily, improved patient reported constipation scale scores and 
increased stool frequency at the 4-w follow-up. Additionally, this 
treatment was well-tolerated; the main adverse effect reported was 
loose stools, which were mild and self-limiting [72].  
Other pharmacological interventions 
Linaclotide, is a newer agent approved for the treatment of chronic 
constipation in the US, UK and some other parts of Europe. It is a 
guanylate cyclase C receptor agonist and thereby promotes 
formation of guanosine monophosphate to increase secretion of 
chloride and bicarbonate into the intestinal lumen [73]. In turn this 
action increases luminal fluid secretion and accelerates intestinal 
transit. Although not studied in patients with PD, two double blind, 
randomised controlled linaclotide trials found doses of 145 mg to 
290 mg improved the frequency of complete spontaneous bowel 
movements vs. placebo [73], thus it may be a useful option if other 
treatments are unsuccessful. As an additional benefit linaclotide 
inhibits pain via the C-fibers and can therefore attenuate abdominal 
pain [74], which is an issue for some PD patients [75]. 
Other new agents in development for chronic constipation include 
elobixibat, an ileal sodium/bile acid cotransporter modulator 
(partial inhibitor), which increases fluid secretion and motility by 
increasing delivery of bile acid to the colon; itopride, an inhibitor of 
acetylcholinesterase and dopamine-2 antagonist; and the ghrelin 
analogues such as relamorelin, which is a ligand for growth hormone 
secretagogue-1a [67]. Although results in chronic constipation in 
general are promising, studies to confirm efficacy in constipation in 
patients with PD are required. 
Finally, a number of older medications licensed for alternative 
indications have been trialled for constipation in PD and may be of 
use when established treatments fail. One case report from the 
1980’s reported colchicine, a drug traditionally used to treat gout, 
given at low doses (0.3-0.6 mg) to be successful in controlling 
constipation in patients that were unresponsive to standard 
measures like other laxatives and enemas [76]. Similarly, Sadjadpour 
[77] provides commentary indicating pyridostigmine bromide, 
typically used to treat myasthenia gravis, is effective at relieving 
constipation for PD patients who fail to respond to ordinary 
measures like bulk-forming laxatives. Pyridostigmine bromide 
works by enhancing intestinal motility but at large doses has been 
reported to cause diarrhoea and abdominal cramps [77]. Nizatidine 
is a selective histamine-2 receptor antagonist, which, unlike other 
histamine antagonists, is thought to promote gastric motility via 
inhibition of acetylcholinesterase, in addition to reducing gastric 
acid secretion [78]. In a recent open-label study nizatidine 150 mg 
twice daily was able to decrease gastric emptying time in patients 
with PD who had delayed gastric emptying at baseline. Interestingly, 
the improvement in colonic transit time was not significant in the 
cohort without stratifying for baseline transit time. In this study 
nizatidine was safe and well-tolerated, and it is available over the 
counter in a number of countries [78].  
Interestingly, a recent retrospective review of medical records found 
use of beta-blockers to be associated with a 70% lower relative risk 
of constipation, while dopaminergic treatments appeared to 
increase the risk of constipation by 50%. As discussed previously, 
intestinal motility is regulated by the autonomic system, thus beta-
blockers may positively augment gastrointestinal transit by 
modulating sympathetic input [79]. Additional research is required 
to determine if/how beta-blockers may be utilised in the 
management of constipation in PD. 
Herbal medicines 
If lifestyle interventions are unsuccessful or inappropriate, and the 
patient requests a herbal option the pharmacist could discuss the 
following herbal medicines that have specifically been assessed for 
treating constipation in PD.  
Dai-Kenchu-tou® 
Dai-Kenchu-tou® is a dietary herb extract containing 50% ginger, 
30% “Nin-jin” (ginseng) and 20% “Sansho” (Japanese pepper, 
Zanthoxylum piperitum), which is used in Eastern countries to ease 
abdominal distension [80]. The pharmacological action of Dai-
Kenchu-tou® to increase gastric motility is likely due to the 
serotonergic 5-HT3 receptor agonist properties of the active 
component, hydroxy-(r)-sanshool hasi [81]. Activation of 
serotonergic neurons in the gastrointestinal system in turn induces 
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acetylcholine release from the myenteric plexus, stimulating the 
gastrointestinal tract to contract [82]. Two case studies have 
documented beneficial effects of Dai-Kenchu-tou® for constipation 
in Parkinson’s patients, including increased frequency of bowel 
movements, shortened colonic transit time and a reduction in 
difficult defaecations [80, 83]. The herb extract was well tolerated; 
the only adverse effect reported was ‘bitter taste’. However, large, 
randomised, blinded and controlled studies need to be performed to 
verify the case report results.  
Rikkunshi-to® 
Rikkunsh-to® is a dietary herb extract containing 17% 
Atractylodis lanceae, 17% Poria cocos, 17% ginseng, 17% Pinellia 
ternata, 9% ginger, 9% orange peel, 9% Ziziphus jujuba and 4% 
Glycyrrhiza, which is given in Eastern countries to alleviate 
vomiting, abdominal distention and pain [84, 85]. The small, open-
labelled study showed Rikkunsh-to® to be well tolerated with the 
only adverse effect reported being its bitter taste. However, while 
Rikkunshi-to® improved gastrointestinal symptoms such as 
appetite loss, bloating and gastric emptying it failed to change the 
patients’ complaints of constipation [85].  
CONCLUSION 
Macrogol (polyethylene glycol) is a safe and effective treatment for 
constipation in patients with PD; pharmacists should consider it a 
first line treatment option. Fibre supplementation with psyllium 
may also be effective and can be initiated early. Lubiprostone 
appears to be a promising option for managing constipation in PD, 
but larger trials with a longer duration of treatment are warranted. 
Based upon the literature discussed above, fig. 1 provides a flow-
chart summary to guide the management of constipation in patients 
with PD in community pharmacy practice.  
It remains to be determined if newer drugs, such as the 5-HT4 
agonist prucalopride or the guanylate cyclase C receptor agonist 
linaclotide, will prove beneficial in treating constipation in patients 
with Parkinson’s disease. Pharmacists are ideally positioned to play 
a key role in both screening for constipation in patients with PD and 
in recommending evidence-based treatments for managing 
constipation in this often difficult to treat patient population. 
 
 
Fig. 1: Flow diagram of the management of constipation in patients with Parkinson’s disease in community pharmacy [23, 39-41, 52, 53, 72] 
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